نتائج البحث - "Selenia Campagna"

1

Identifying the link between multiple myeloma and neurofibromatosis type I

المؤلفون: Tommaso Caravita di Toritto, Attilio Tordi, Cristina Andrizzi, Selenia Campagna, Angela Rago, Agostina Siniscalchi

المصدر: Blood research

مصطلحات موضوعية: Oncology, Neurofibromatosis type I, medicine.medical_specialty, business.industry, Internal medicine, medicine, MEDLINE, Hematology, business, Link (knot theory), medicine.disease, Letters to the Editor, Multiple myeloma

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9a933abfd4e52f79fb75292435444e66
http://europepmc.org/articles/PMC7536567

2

Cytogenetic and molecular diagnostic characterization combined to postconsolidation minimal residual disease assessment by flow cytometry improves risk stratification in adult acute myeloid leukemia

المصدر: Blood. 116:2295-2303

مصطلحات موضوعية: Adult, Male, medicine.medical_specialty, Pathology, Neoplasm, Residual, Myeloid, Adolescent, Prognosis, adolescent, male, young adult, middle aged, mutation, female, risk factors, neoplasm, residual, fms-like tyrosine kinase 3, humans, flow cytometry, nuclear proteins, antineoplastic combined chemotherapy protocols, aged, cytogenetic analysis, leukemia, myeloid, acute, adult, Immunology, Biochemistry, Gastroenterology, residual, Young Adult, Risk Factors, hemic and lymphatic diseases, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, medicine, Humans, Risk factor, Aged, Hematology, business.industry, leukemia, acute, Nuclear Proteins, Cancer, Adult Acute Myeloid Leukemia, Cell Biology, Middle Aged, Flow Cytometry, medicine.disease, Minimal residual disease, body regions, Leukemia, Myeloid, Acute, Leukemia, medicine.anatomical_structure, fms-Like Tyrosine Kinase 3, Cytogenetic Analysis, Mutation, Fms-Like Tyrosine Kinase 3, Female, myeloid, business, Settore MED/15 - Malattie del Sangue, Nucleophosmin, neoplasm

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::63acb2ecfb1062b4f5c7c409a4389322
https://doi.org/10.1182/blood-2009-12-258178

3

Dexamethasone plus rituximab yields higher sustained response rates than dexamethasone monotherapy in adults with primary immune thrombocytopenia

المساهمون: Zaja F, Baccarani M, Mazza P, Bocchia M, Gugliotta L, Zaccaria A, Vianelli N, Defina M, Tieghi A, Amadori S, Campagna S, FerraraF, Angelucci E, Usala E, Cantoni S, Visani G, Fornaro A, Rizzi R, Zaja, Francesco, Baccarani, M, Mazza, P, Bocchia, M, Gugliotta, L, Zaccaria, A, Vianelli, N, Defina, M, Tieghi, A, Amadori, S, Campagna, S, Ferrara, F, Angelucci, E, Usala, E, Cantoni, S, Visani, G, Fornaro, A, Rizzi, R, DE STEFANO, V, Casulli, F, Battista, Ml, Isola, Miriam, Soldano, F, Gamba, E, Fanin, Renato

مصطلحات موضوعية: Adult, Male, medicine.medical_specialty, Time Factors, Combination therapy, medicine.drug_class, medicine.medical_treatment, Immunology, Splenectomy, Salvage therapy, Biochemistry, Gastroenterology, Dexamethasone, Antibodies, Monoclonal, Murine-Derived, Refractory, dexamethasone, purpura, thrombocytopenic, idiopathic, rituximab, salvage therapy, platelet count measurement, arm, Internal medicine, hemic and lymphatic diseases, Antineoplastic Combined Chemotherapy Protocols, medicine, Humans, Adverse effect, Aged, Salvage Therapy, Purpura, Thrombocytopenic, Idiopathic, Platelet Count, business.industry, Antibodies, Monoclonal, Cell Biology, Hematology, Middle Aged, Surgery, Corticosteroid, Female, Rituximab, business, Settore MED/15 - Malattie del Sangue, medicine.drug